Clinical Impact of Levalbuterol versus Racemic Albuterol on Cardiovascular Vital Signs in Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Author(s)

Mondin, J. J., Cottingham, L. G., Ratliff, P. D.

Author's Affiliation

Abstract

More pharmaceutical companies are utilizing the stereochemistry of racemic mixtures as a new method of drug discovery, which make up about 25% of agents on the market.  Levalbuterol, the R-enantiomer of albuterol, is now marketed for treatment of asthma in the United States with the claim of a lower incidence of cardiac side effects. This study aims to examine the impact of each agent on cardiovascular vital signs.

Keywords

Levalbuterol, racemic albuterol, tachycardia, R-albuterol

Cite This Article

Mondin, J. J., Cottingham, L. G., & Ratliff, P. D. (2015). Clinical Impact of Levalbuterol versus Racemic Albuterol on Cardiovascular Vital Signs in Patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD), International Journal for Pharmaceutical Research Scholars (IJPRS), 4(4), 63-68.